In the 12 months to Nov 19, 2026, on the open market: bought $532.2M of PBLS, BBTX, PEPG and 3 more; sold $94.7M of SEPN, SION, LENZ and 1 more. Filed a median of 2 business days after the trade.
Open-market purchases and sales this filer reported on SEC Form 4, by the day traded. Insiders have two business days to file. A sale marked 10b5-1 was made under a plan adopted in advance. How to read these
Insider purchases above the line: $532.2MInsider sales below: $94.7M
Dollar value of open-market purchases and sales reported on SEC Form 4, by the month traded. Sales include pre-arranged 10b5-1 plan sales.
SGPBought: SpyGlass Pharma, Inc. Nov 16, 20261,000 sharesfiled Nov 18, 20265,967,439 shares held indirectly after, as filedfiling$32K
PEPGBought: PepGen Inc. Nov 13, 20268,625,000 sharesfiled Nov 17, 202627,179,273 shares held indirectly after, as filedfiling$43.1M
BBTXBought: Bambusa Therapeutics, Inc. Nov 2, 20262,500,000 sharesfiled Nov 3, 20262 transactionsfiling$40.0M
BBTXBought: Bambusa Therapeutics, Inc. Oct 30, 2026453,820 sharesfiled Nov 3, 20262 transactionsfiling$6.6M
LENZSold: LENZ Therapeutics, Inc. Oct 29, 20262,718,684 sharesfiled Nov 2, 20263 transactionsfiling$9.1M
ARTVBought: Artiva Biotherapeutics, Inc. Jul 17, 20267,882 sharesfiled Jul 20, 202616,977,927 shares held indirectly after, as filedfiling$71K
ARTVBought: Artiva Biotherapeutics, Inc. Jul 16, 2026152,472 sharesfiled Jul 20, 202616,970,045 shares held indirectly after, as filedfiling$1.4M
ARTVBought: Artiva Biotherapeutics, Inc. Jul 13, 20266,522 sharesfiled Jul 23, 202616,817,543 shares held indirectly after, as filedfiling$58K
ARTVBought: Artiva Biotherapeutics, Inc. Jul 10, 202615,102 sharesfiled Jul 14, 202616,811,021 shares held indirectly after, as filedfiling$135K
ARTVBought: Artiva Biotherapeutics, Inc. Jun 26, 20261,876 sharesfiled Jun 29, 202616,795,919 shares held indirectly after, as filedfiling$17K
ARTVBought: Artiva Biotherapeutics, Inc. Jun 25, 202631,000 sharesfiled Jun 29, 202616,794,043 shares held indirectly after, as filedfiling$275K
HOWLSold: Werewolf Therapeutics, Inc. Jun 17, 2026416,911 sharesfiled Jun 22, 20262 transactionsfiling$146K
COAGBought: Hemab Therapeutics Holdings, Inc. Jun 16, 202661,523 sharesfiled Jun 17, 20266,444,637 shares held indirectly after, as filedfiling$1.5M
ARTVBought: Artiva Biotherapeutics, Inc. Jun 16, 2026124,893 sharesfiled Jun 16, 202616,763,043 shares held indirectly after, as filedfiling$1.1M
HOWLSold: Werewolf Therapeutics, Inc. Jun 16, 2026149,625 sharesfiled Jun 16, 20262 transactionsfiling$55K
COAGBought: Hemab Therapeutics Holdings, Inc. Jun 15, 20266,146 sharesfiled Jun 17, 20266,383,114 shares held indirectly after, as filedfiling$153K
ARTVBought: Artiva Biotherapeutics, Inc. Jun 15, 202615,414 sharesfiled Jun 16, 202616,638,150 shares held indirectly after, as filedfiling$139K
HOWLSold: Werewolf Therapeutics, Inc. Jun 15, 2026128,770 sharesfiled Jun 16, 20262 transactionsfiling$50K
ARTVBought: Artiva Biotherapeutics, Inc. Jun 12, 2026391,019 sharesfiled Jun 16, 202616,622,736 shares held indirectly after, as filedfiling$3.4M
HOWLSold: Werewolf Therapeutics, Inc. Jun 12, 2026170,441 sharesfiled Jun 16, 20262 transactionsfiling$68K
PBLSBought: Parabilis Medicines, Inc. Jun 11, 202621,188,750 sharesfiled Jun 15, 20262 transactionsfiling$423.8M
Source: SEC Form 4 filings. Value is shares × the price reported on the filing; a filing whose price failed Lytir's check against the market price is left out, and a trade that related owners reported on separate forms is counted once. Filings can be late, amended or wrong at the source; see methodology.
Stakes filed (13D/13G)
Anyone who comes to hold more than 5% of a company's voting shares must tell the SEC. A Schedule 13D is filed by a holder who may seek to influence the company; a 13G by one who states it is a passive investor. An amendment updates an earlier filing, and a stake reported as 0% means the holder says it has sold all, or nearly all, of its shares. Filings made under this filer's SEC CIK in the same 12 months, newest first; the figure is the percentage the filing states. Every recent 13D and 13G
PEPGRA Capital Management, L.P. filed Nov 17, 2026Schedule 13D/Amay seek influence28,742,212 sharesissuer: PEPGEN INC.filing30.5%
PALIRA Capital Management, L.P. filed Nov 16, 2026Schedule 13G/Apassiveissuer: Palisade Bio, Inc.filing9.9%
KPTIRA Capital Management, L.P. filed Nov 16, 2026Schedule 13G/Apassiveissuer: Karyopharm Therapeutics Inc.filing9.9%
QTTBRA Capital Management, L.P. filed Nov 16, 2026Schedule 13G/Apassiveissuer: Q32 Bio Inc.filing9.9%
CCCCRA Capital Management, L.P. filed Nov 16, 2026Schedule 13G/Apassiveissuer: C4 Therapeutics, Inc.filing9.9%
EQRA Capital Management, L.P. filed Nov 16, 2026Schedule 13G/Apassiveissuer: EQUILLIUM, INC.filing9.9%
UNCYRA Capital Management, L.P. filed Nov 16, 2026Schedule 13G/Apassiveissuer: Unicycive Therapeutics, Inc.filing9.9%
TSHARA Capital Management, L.P. filed Nov 16, 2026Schedule 13G/Apassiveissuer: TAYSHA GENE THERAPIES, INC.filing9.9%
NAMSRA Capital Management, L.P. filed Nov 16, 2026Schedule 13G/Apassiveissuer: NewAmsterdam Pharma Company N.V.filing9.9%
OVIDRA Capital Management, L.P. filed Nov 16, 2026Schedule 13G/Apassiveissuer: OVID THERAPEUTICS INC.filing7.8%
GHRSRA Capital Management, L.P. filed Nov 16, 2026Schedule 13G/Apassiveissuer: GH Research PLCfiling5.3%
JBIORA Capital Management, L.P. filed Nov 16, 2026Schedule 13G/Apassiveissuer: Jade Biosciences, Inc.filing2.9%
ZLABRA Capital Management, L.P. filed Nov 16, 2026Schedule 13G/Apassiveissuer: Zai Lab Limitedfiling2.5%
BCRXRA Capital Management, L.P. filed Nov 16, 2026Schedule 13G/Apassiveissuer: BioCryst Pharmaceuticals, Inc.filing0%
EVMNRA Capital Management, L.P. filed Nov 10, 2026Schedule 13D/Amay seek influence3,494,638 sharesissuer: Evommune, Inc.filing8.5%
CLYMRA Capital Management, L.P. filed Nov 9, 2026Schedule 13D/Amay seek influence23,941,277 sharesissuer: Climb Bio, Inc.filing33%
BBTXRA Capital Management, L.P. filed Nov 6, 2026Schedule 13Dmay seek influence7,429,758 sharesissuer: Bambusa Therapeutics, Inc.filing14.6%
SLDBRA Capital Management, L.P. filed Nov 6, 2026Schedule 13D/Amay seek influence12,036,126 sharesissuer: SOLID BIOSCIENCES INC.filing10.8%
LENZRA Capital Management, L.P. filed Nov 2, 2026Schedule 13D/Amay seek influence70,533 sharesissuer: LENZ THERAPEUTICS, INC.filing0.2%
TCXBRA Capital Management, L.P. filed Oct 26, 2026Schedule 13Gpassiveissuer: TCGX Acquisition Corp. IIfiling7.2%
ALECRA Capital Management, L.P. filed Oct 26, 2026Schedule 13Gpassiveissuer: Alector, Inc.filing5.1%
FLSCRA Capital Management, L.P. filed Oct 22, 2026Schedule 13Gpassiveissuer: Frazier Life Sciences Acquisition Corp. IIfiling9%
HOWLRA CAPITAL MANAGEMENT, L.P. filed Jun 26, 2026Schedule 13D/Amay seek influence2,915,742 sharesissuer: Werewolf Therapeutics, Inc.filing6%
SLDBRA CAPITAL MANAGEMENT, L.P. filed Jun 24, 2026Schedule 13D/Amay seek influence12,036,126 sharesissuer: Solid Biosciences Inc.filing11.9%
HOWLRA CAPITAL MANAGEMENT, L.P. filed Jun 22, 2026Schedule 13D/Amay seek influence3,654,307 sharesissuer: Werewolf Therapeutics, Inc.filing7.5%
PBLSRA CAPITAL MANAGEMENT, L.P. filed Jun 18, 2026Schedule 13Dmay seek influence28,933,371 sharesissuer: Parabilis Medicines, Inc.filing23.8%
ARTVRA CAPITAL MANAGEMENT, L.P. filed Jun 15, 2026Schedule 13D/Amay seek influence17,811,623 sharesissuer: Artiva Biotherapeutics, Inc.filing36.6%
HOWLRA CAPITAL MANAGEMENT, L.P. filed Jun 15, 2026Schedule 13D/Amay seek influence5,138,703 sharesissuer: Werewolf Therapeutics, Inc.filing10.6%
Other Form 4 entries
Not counted above: entries this filer reported on Form 4 in the same 12 months that are not open-market purchases or sales. Each entry is one line of a filing.
FRNM: grant or award (code A), 7 entries, Jul 20, 2026
CLYM: option exercise or conversion (code M), 4 entries, Sep 28, 2026
WVE: grant or award (code A), 1 entry, Oct 5, 2026
Code A
A grant or award from the company, such as stock given as pay.
Code C
A conversion of a derivative security, such as preferred stock or units, into shares.
Code J
Another acquisition or disposition, described in the filing's footnotes.
Code M
An exercise or conversion of a derivative security received from the company, such as stock options.
Code X
An exercise of an in-the-money or at-the-money derivative security.
Source: the same SEC Form 4 filings. The codes are the SEC's own transaction codes; the meanings above are a plain-words reading of the SEC's Form 4 instructions.